Literature DB >> 16319717

Adreno-leukodystrophy: oxidative stress of mice and men.

James M Powers1, Zhengtong Pei, Ann K Heinzer, Rebecca Deering, Ann B Moser, Hugo W Moser, Paul A Watkins, Kirby D Smith.   

Abstract

X-linked adreno-leukodystrophy is a progressive, systemic peroxisomal disorder that affects primarily nervous system myelin and axons as well as the adrenal cortex. Several divergent clinical phenotypes can occur in the same family; thus, there is no correlation between the clinical phenotype and the mutation in the ABCD1 gene in this disease. The most urgent and unresolved clinical issue is the fulminant inflammatory (immune) demyelination of the central nervous system in which a variety of cellular participants, cytokines, and chemokines are noted. A knockout mouse model exhibits mitochondrial deficits and axonal degeneration, but not inflammatory demyelination. To determine whether oxidative stress and damage might play a pathogenic role, we assessed standard biochemical and immunohistochemical markers of such activity both in our knockout mouse model and patients. We find that oxidative stress, as judged by increased immunoreactivity for the mitochondrial manganese-superoxide dismutase, is present in the knockout mouse liver, adrenal cortex, and renal cortex, tissues that normally express high levels of ABCD1 but no evidence of oxidative damage. The brain does not exhibit either oxidative stress or damage. On the other hand, both the human adrenal cortex and brain show evidence of oxidative stress (e.g. hemoxygenase-1 and manganese-superoxide dismutase) and oxidative damage, particularly from lipid peroxidation (4-hydroxynonenal and malondialdehyde). The presence of nitrotyrosylated proteins is strong circumstantial evidence for the participation of the highly toxic peroxynitrite molecule, whereas the demonstration of interferon gamma and interleukin-12 is indicative of a TH1 response in the inflammatory demyelinative lesions of the cerebral phenotype. These differences between the adreno-leukodystrophy mouse and human patients are intriguing and may provide a clue to the phenotypic divergence in this disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16319717     DOI: 10.1097/01.jnen.0000190064.28559.a4

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  50 in total

1.  ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.

Authors:  Mauhamad Baarine; Craig Beeson; Avtar Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

2.  Intensity of MRI Gadolinium Enhancement in Cerebral Adrenoleukodystrophy: A Biomarker for Inflammation and Predictor of Outcome following Transplantation in Higher Risk Patients.

Authors:  W P Miller; L F Mantovani; J Muzic; J B Rykken; R S Gawande; T C Lund; R M Shanley; G V Raymond; P J Orchard; D R Nascene
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-01       Impact factor: 3.825

Review 3.  The Landscape of Hematopoietic Stem Cell Transplant and Gene Therapy for X-Linked Adrenoleukodystrophy.

Authors:  Eric J Mallack; Bela Turk; Helena Yan; Florian S Eichler
Journal:  Curr Treat Options Neurol       Date:  2019-11-25       Impact factor: 3.598

4.  Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy.

Authors:  Mushfiquddin Khan; Jaspreet Singh; Anne G Gilg; Takuhiro Uto; Inderjit Singh
Journal:  J Lipid Res       Date:  2010-02-20       Impact factor: 5.922

5.  Childhood cerebral X-linked adrenoleukodystrophy: diffusion tensor imaging measurements for prediction of clinical outcome after hematopoietic stem cell transplantation.

Authors:  A M McKinney; D Nascene; W P Miller; J Eisengart; D Loes; M Benson; J Tolar; P J Orchard; R S Ziegler; L Zhang; J Provenzale
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-16       Impact factor: 3.825

Review 6.  Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy.

Authors:  Johannes Berger; Aurora Pujol; Patrick Aubourg; Sonja Forss-Petter
Journal:  Brain Pathol       Date:  2010-07       Impact factor: 6.508

Review 7.  Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis.

Authors:  Inderjit Singh; Aurora Pujol
Journal:  Brain Pathol       Date:  2010-07       Impact factor: 6.508

8.  No evidence for the reversal of adrenal failure after hematopoietic cell transplantation in X-linked adrenoleukodystrophy.

Authors:  A Petryk; L E Polgreen; S Chahla; W Miller; P J Orchard
Journal:  Bone Marrow Transplant       Date:  2012-03-05       Impact factor: 5.483

9.  Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy.

Authors:  L Morató; M Ruiz; J Boada; N Y Calingasan; J Galino; C Guilera; M Jové; A Naudí; I Ferrer; R Pamplona; M Serrano; M Portero-Otín; M F Beal; S Fourcade; A Pujol
Journal:  Cell Death Differ       Date:  2015-03-27       Impact factor: 15.828

Review 10.  Peroxisomal dysfunction in inflammatory childhood white matter disorders: an unexpected contributor to neuropathology.

Authors:  Inderjit Singh; Avtar K Singh; Miguel A Contreras
Journal:  J Child Neurol       Date:  2009-07-15       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.